Skip to main content
SpringerLink
Log in

The epidemiology of the antiphospholipid syndrome: Who is at risk?

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Arterial and venous thrombosis are the most common and clinically relevant events of the so-called antiphospholipid syndrome; they are reported in approximately one third of patients with the antiphospholipid (aPL) antibodies. APL antibodies are part of a wide family of immunoglobulins directed against proteins complexed with negatively charged phospholipids. They include lupus anticoagulants (LA), anticardiolipin (aCL) antibodies, and the most recently recognized anti-beta-2-glycoprotein I (β2-GPI) and antiprothrombin (aPT) antibodies. Previous thrombotic events and the presence of LA, particularly if identified by the dilute Russell viper venom test, appear to be the strongest risk factors for vascular complications. High-titer aCL antibodies have been reported to be associated with an increased thrombotic tendency, but this was not confirmed in all studies. The data only partially support the concept that anti-β2-GPI and aPT antibodies may be considered as independent risk factors for thrombosis. Further prospective studies are required.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Triplett DA: Lupus anticoagulant/antiphospholipid-protein antibodies: the great imposters. Lupus 1996, 5:431–435.

    PubMed  CAS  Google Scholar 

  2. Greaves M: Antiphospholipid antibodies and thrombosis. Lancet 1999, 353:1348–1353. This article reviews the nature of antiphospholipid antibodies and their relationship with thrombotic complications. Important unresolved issues in diagnosis and management are highlighted with the aim to address future investigations.

    Article  PubMed  CAS  Google Scholar 

  3. Bevers EM, Galli M, Barbui T, et al.: Lupus anticoagulant IgGs (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemostas 1991, 66:629–632.

    CAS  Google Scholar 

  4. Galli M, Comfurius P, Maassen C, et al.: Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990, 336:177–178.

    Google Scholar 

  5. Arvieux J, Roussel B, Jacob MC, Colomb MG: Measurement of antiphospholipid antibodies by ELISA using b2-glycoprotein I as an antigen. J Immunol Meth 1991, 143:223–239.

    Article  CAS  Google Scholar 

  6. Hughes GRV: The antiphospholipid syndrome: ten years on. Lancet 1993, 342:341–344.

    Article  PubMed  CAS  Google Scholar 

  7. Greaves M, Cohen H, Machin SJ, Mackie I: Guidelines on the investigation and management of the antiphospholipid syndrome. Br J Haematol 2000, 109:704–715. This paper reports the guidelines for diagnosis and treatment of APS drawn by the Haemostasis and Thrombosis Task Force of the British Committee for Standards in Haematology. Clear and updated recommendations are given for laboratory investigations and therapeutic approach to these patients.

    Article  PubMed  CAS  Google Scholar 

  8. Tanne D, Levine SR, Kittner SJ: Epidemiology of antiphospholipid antibodies and vascular disease. In Clinical Approach to Antiphospholipid Antibodies. Edited by SR Levine and RL Brey. Boston: Butterworth Heinemann; 2000:1–18.

    Google Scholar 

  9. Vila P, Hernandez MC, Lopez-Fernandez MF, Battle J: Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects. Thromb Haemostas 1994, 72:209–213.

    CAS  Google Scholar 

  10. Vianna JL, Khamashta MA, Ordi-Ros J, et al.: Comparison of the primary and secondary antiphospholipid syndrome: a European multicenter study of 114 patients. Am J Med 1994, 96:3–9.

    Article  PubMed  CAS  Google Scholar 

  11. Love PE, Santoro SA: Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Ann Intern Med 1990, 112:682–698.

    PubMed  CAS  Google Scholar 

  12. Hess DC, Brey RL: Mechanisms of thrombosis and experimental models. In Clinical Approach to Antiphospholipid Antibodies. Edited by Levine SR and Brey RL. Boston: Butterworth Heinemann; 2000:43–67.

    Google Scholar 

  13. Pierangeli SS, Barker JH, Stikovac D, et al.: Effect of human IgG antiphospholipid antibodies on an in vivo thrombosis model in mice. Thromb Haemostas 1994, 71:670–674.

    CAS  Google Scholar 

  14. Finazzi G, Brancaccio V, Moia M, et al.: Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. Am J Med 1996, 100:530–536.

    Article  PubMed  CAS  Google Scholar 

  15. Ramsey-Goldman R, Kulzer JE, Kuller LH, et al.: Pregnancy outcome and anti-cardiolipin antibody in women with systemic lupus erythematosus. Am J Epidemiol 1993, 138:1057–1069.

    PubMed  CAS  Google Scholar 

  16. Derksen RHWM, de Groot PG, Kater L, et al.: Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment. Ann Rheum Dis 1993, 52:689–692.

    Article  PubMed  CAS  Google Scholar 

  17. Rosove MH, Brewer PMC: Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med 1992, 117:303–308.

    PubMed  CAS  Google Scholar 

  18. Khamashta MA, Cuadrado MJ, Mujic F, et al.: The management of thrombosis in the antiphospholipid syndrome. N Engl J Med 1995, 332:993–997.

    Article  PubMed  CAS  Google Scholar 

  19. Al-Sayegh FA, Ensworth S, Huang S, Stein HB, Klinkhoff AV: Hemorrhagic complications of longterm anticoagulant therapy in 7 patients with systemic lupus erythematosus and antiphospholipid syndrome. J Rheumatol 1997, 24:1716–1718.

    PubMed  CAS  Google Scholar 

  20. Ginsberg JS, Wells PS, Brill-Edwards P, et al.: Antiphospholipid antibodies and venous thromboembolism. Blood 1995, 86:3685–3691.

    PubMed  CAS  Google Scholar 

  21. Prandoni P, Simioni P, Girolami A: Antiphospholipid antibodies, recurrent thromboembolism and intensity of warfarin anticoagulation. Thromb Haemostas 1996, 75:859.

    CAS  Google Scholar 

  22. Rance A, Emmerich J, Fiessinger JN: Antiphospholipid antibodies and recurrent thromboembolism. Thromb Haemostas 1997, 77:221–222.

    CAS  Google Scholar 

  23. Schulman S, Svenungsson E, Granqvist S: Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Am J Med 1998, 104:332–338. This paper shows that the presence of elevated titers of anticardiolipin antibodies 6 months after an episode of venous thromboembolism is a predictor for an increased risk of recurrence and death. Patients with anticardiolipin antibodies and venous thromboembolism seem to benefit from prolonged oral anticoagulation targeted at an INR of 2.0 to 2.85.

    Article  PubMed  CAS  Google Scholar 

  24. Gonzales-Trujillo JL, Villegas-Jimenez A, Rios-Luna N, et al.: Conventional intensity may be as effective as high intensity oral anticoagulation in the antiphospholipid syndrome. J Autoimmun 2000, 15:A22.

    Google Scholar 

  25. Finazzi G, Barbui T: Feasibility of a randomized clinical trial for the prevention of recurrent thrombosis in the antiphospholipid syndrome: the WAPS project. Ann Med Interne (Paris) 1996, 147:38–41.

    CAS  Google Scholar 

  26. Galli M: Which antiphospholipid antibodies should be measured in the antiphospholipid syndrome? Haemostasis 2000, 30:57–62. This paper presents the results of an analysis of studies published over a 10-year period that addressed the association between aPL and thrombosis in patients with APS. Lupus anticoagulants appear to be the strongest risk factor for thromboembolic events. However, anticardiolipin, anti-beta-2-glycoprotein and antiprothrombin antibodies are not clearly demonstrated to be independent predictors of vascular complications.

    Article  PubMed  CAS  Google Scholar 

  27. Horbach DA, van Oort E, Donders RCJM, Derksen RHWM, deGroot PG: Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus: comparison between different assays for the detection of antiphospholipid antibodies. Thromb Haemost 1996, 76:916–924.

    PubMed  CAS  Google Scholar 

  28. Galli M, Comfurius P, Barbui T, Zwaal RFA, Bevers EM: Anticoagulant activity of b2-glycoprotein I is potentiated by a distinct subgroup of anticardiolipin antibodies. Thromb Haemost 1992, 68:297–300.

    PubMed  CAS  Google Scholar 

  29. Brandt JT, Triplett DA, Alving B, Scharrer I: Criteria for the diagnosis of lupus anticoagulants: an update. Thromb Haemost 1995, 74:1185–1190.

    PubMed  CAS  Google Scholar 

  30. Thiagarajan P, Pengo V, Shapiro SS: The use of the dilute Russell’s viper venom time for the diagnosis of lupus anticoagulants. Blood 1986, 68:869–874.

    PubMed  CAS  Google Scholar 

  31. Norbis F, Barbui T, Galli M: Dilute Russell’s viper venom time and colloidal silica clotting time for the identification of the phospholipid-dependent inhibitors of coagulation. Thromb Res 1997, 85:427–431.

    Article  PubMed  CAS  Google Scholar 

  32. Exner T, Rickard KA, Kronenberg H: A sensitive test demonstrating lupus anticoagulant and its behavioural patterns. Br J Haematol 1978, 40:143–151.

    PubMed  CAS  Google Scholar 

  33. Galli M, Finazzi G, Bevers EM, Barbui T: Kaolin clotting time and dilute Russell’s viper venom time distinguish between prothrombin and b2-glycoprotein I-dependent antiphospholipid antibodies. Blood 1995, 86:617–663.

    PubMed  CAS  Google Scholar 

  34. Galli M, Finazzi G, Norbis F, et al.: The risk of thrombosis in patients with lupus anticoagulants is predicted by their specific coagulation profile. Thromb Haemost 1999, 81:695–700.

    PubMed  CAS  Google Scholar 

  35. Simmelink MJA, Horbach DA, Voort E, Derksen RHWM, deGroot P: dRVVT is a much better predictor than KCT for the risk of thrombosis. Lupus 1998, 7:219.

    Google Scholar 

  36. Galli M, Dlott J, Norbis F, et al.: Lupus anticoagulant and thrombosis: clinical association of different coagulation and immunologic tests. Thromb Haemostas 2000, 84:1012–1016. This paper demonstrates that dilute Russell’s viper venom time (dRVVT) rather than other coagulation or ELISA tests are able to identify lupus anticoagulant-positive patients at risk of thrombosis. This property appears common to several commercially available kits, making this test the ideal target of future standardization studies.

    CAS  Google Scholar 

  37. Callahan JB, Manares CC, Moll S, Ortel TL: Inability to distinguish between thrombotic and non-thrombotic antiphospholipid antibody positive patients with kaolin clotting time and dilute Russell’s viper venom assay ratio. Lupus 1996, 5:530.

    Google Scholar 

  38. Norbis F, Barbui T, Galli M: Comparison of two Russell’s viper venom time (dRVVT) for distinguishing the phospholipiddependent inhibitors of coagulation. Thromb Haemostas 1997:pp331.

  39. Foster WM, Triplett DA, Barna LK: Evaluation of 7 dilute Russell’s viper venom time (dRVVT) kits. Lupus 1994, 3:351.

    Google Scholar 

  40. Lawrie AS, Mackie J, Purdy S, Machin SJ: The sensitivity and specificity of commercial reagents for the detection of lupus anticoagulant show marked differences in performance between photo-optical and mechanical coagulometers. Thromb Haemost 1999, 81:758–762.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Divisione di Ematologia, Ospedali Riuniti, Largo Barozzi 1, 24128, Bergamo, Italy

    Guido Finazzi MD

Authors
  1. Guido Finazzi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Finazzi, G. The epidemiology of the antiphospholipid syndrome: Who is at risk?. Curr Rheumatol Rep 3, 271–276 (2001). https://doi.org/10.1007/s11926-001-0030-5

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-001-0030-5

Keywords

Search

Navigation